United States human insulin market is expected to show an exponential growth with an impressive CAGR in the forecast period, 2022-2026. The market growth can be attributed to growing geriatric population, increasing diabetic patients, rising prevalence of obesity, and -increasing demand of better and efficient treatment. Increasing number of young populations being infected of diabetes and irregular sugar level is increasing. This increase in the number of young diabetics is anticipated to drive the growth of the market growth in the next five years. Technological advancements in the devices and appliances making life easier and comfortable, are driving the young adults toward obesity, lazy lifestyle and many health issues that irregulates blood sugar level in their bodies, which is indirectly affecting the growth of the United States human insulin market in the next five years. Cost-effectiveness, reimbursement prices and strict regulatory requirements for approval of insulin is anticipated to support the growth of the United States human insulin market in the next five years.

Human insulin refers to synthetic insulin which is laboratory grown to mimic the insulin in humans. The laboratory created human insulin created by insulin proteins within E-coli bacteria (Escherichia Coli). They are present in two forms short acting regular form and neutral protamine hagedron (NPH) insulin form is also known as isophane insulin which is a suspension meaning that the insulin vial should be rolled or repeatedly turned upside down to ensure the solution is uniformly cloudy.

The United States human insulin market is segmented by indication, products, type, onset time, brand, competitional landscape, and regional distribution. Based on indication, the market is further bifurcated into type 1 diabetes, and type 2 diabetes. Type-I diabetes is likely to hold the largest market share as human insulin is the most important treatment method for the people suffering from type-I diabetes. The population suffering from type 1 diabetes requires insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle, to prevent complications. The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients' use, curbing out maximum side effects, and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, and thus anticipated to drive the growth of the market in the upcoming five years.

Holding largest shares of the market, a partial list of the market players includes Novo Nordisk Inc., Sanofi-Aventis US LLC, Eli Lilly and Company, Nektar Therapeutics, Mannkind Corporation, A-S Medication Solutions, RemedyRepack Inc., Becton, Dickinson and Company, B. Braun USA, Baxter International Inc., among others. The market players are highly involved in the research and development of the technologically advanced form of synthetic and laboratory synthesized human insulin. Moreover, surge in the demand of efficient and effective treatment for the diabetes and effective method of administration along with the medical devices employed for the administration of the human insulin is instigating more and diverse research and development. Market players may adopt partnerships and acquisition as other strategic recommendations.

Years considered for this report:

Historical Years: 2016 – 2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022 – 2026

Objective of the Study:

  • To analyze the historical growth of the market size of United States human insulin market from 2016 to 2019.
  • To estimate and forecast the market size of United States human insulin market from 2020 to 2026 and growth rate until 2026. 
  • To classify and forecast United States human insulin market based on indication, products, type, onset time, brand, competitional landscape, and regional distribution.
  • To identify dominant region or segment in the United States human insulin market.
  • To identify drivers and challenges for United States human insulin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in United States human insulin market.
  • To identify and analyze the profile of leading players operating in United States human insulin market.
  • To identify key sustainable strategies adopted by market players in United States human insulin market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of United States human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Human insulin manufacturers, end users, and other stakeholders
  • Distributers and suppliers of the products and other stakeholders
  • Organizations, forums, and alliances related to human insulin products
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, United States human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • United States Human Insulin Market, By Indication:
    • Type 1 Diabetes
    • Type 2 Diabetes
  • United States Human Insulin Market, By Products:

o   Insulin Pens

o   Insulin Pumps

o   Infusion System

o   Injection

  • United States Human Insulin Market, By Type:

o   Basal

o   Bolus

o   Pre-Mixed

o   Biosimilar

o   Traditional

  • United States Human Insulin Market, By Onset Time:
    • Rapid Acting
    • Short Acting
    • Intermediate Acting
    • Long Lasting
    • Others
  • United States Human Insulin Market, By Brand:
    • Lantus
    • Humulin R
    • Novolin R
    • Humulin N
    • Exubera
    • Others
  • United States Human Insulin Market, By Region:
    • South West
    • Mid-West
    • North East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States human insulin market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
United States Human Insulin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

1.     Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on United States Human Insulin Market

4.    Executive Summary

5.    Voice of Customers

6.    United States Human Insulin Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Indication (Type 1 Diabetes v/s Type 2 Diabetes)

6.2.2.     By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)

6.2.3.     By Type (Basal, Bolus, Pre-Mixed, Biosimilar, Traditional)

6.2.4.     By Onset Time (Rapid Acting, Short Acting, Intermediate Acting, Long Lasting, Others)

6.2.5.     By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Others)

6.2.6.     By Region

6.2.7.     By Company (2020)

6.3.  Product Market Map

7.    United States Rapid Acting Human Insulin Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Indication

7.2.2.     By Products

7.2.3.     By Type

7.2.4.     By Brand

8.    United States Short Acting Human Insulin Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Indication

8.2.2.     By Products

8.2.3.     By Type

8.2.4.     By Brand

9.    United States Intermediate Acting Human Insulin Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Indication

9.2.2.     By Products

9.2.3.     By Type

9.2.4.     By Brand

10.  United States Long Lasting Human Insulin Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Indication

10.2.2.  By Products

10.2.3.  By Type

10.2.4.  By Brand

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

13.  Policy & Regulatory Landscape

14.  Import-Export Analysis

15.  United States Economic Profile

16.  Competitive Landscape

16.1.              Competition Outlook

16.2.              Company Profiles

16.2.1.  Novo Nordisk Inc.

16.2.2.  Sanofi-Aventis US LLC

16.2.3.  Eli Lilly and Company

16.2.4.  Nektar Therapeutics

16.2.5.  Mannkind Corporation

16.2.6.  A-S Medication Solutions

16.2.7.  RemedyRepack Inc.

16.2.8.  Becton, Dickinson and Company

16.2.9.  B. Braun USA

16.2.10.                Baxter International Inc.

17.  Strategic Recommendations

18. About Us & Disclaimer